Cargando…

Does HPV Subtype Predict Outcomes in Head and Neck Cancers?

BACKGROUND: Recently, reanalysis of The Cancer Genome Atlas study demonstrated that human papillomavirus (HPV) genotypes in head and neck cancers other than HPV-16 have inferior survival to HPV-16-positive tumors. We aimed to examine the association of HPV subtypes and survival in a large cohort of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziai, Hedyeh, Warner, Andrew, Mundi, Neil, Patel, Krupal, Chung, Eun Jae, Howlett, Christopher J., Plantinga, Paul, Yoo, John, MacNeil, S. Danielle, Fung, Kevin, Mymryk, Joe S., Barrett, John W., Palma, David A., Nichols, Anthony C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006754/
https://www.ncbi.nlm.nih.gov/pubmed/33824664
http://dx.doi.org/10.1155/2021/6672373
_version_ 1783672370013143040
author Ziai, Hedyeh
Warner, Andrew
Mundi, Neil
Patel, Krupal
Chung, Eun Jae
Howlett, Christopher J.
Plantinga, Paul
Yoo, John
MacNeil, S. Danielle
Fung, Kevin
Mymryk, Joe S.
Barrett, John W.
Palma, David A.
Nichols, Anthony C.
author_facet Ziai, Hedyeh
Warner, Andrew
Mundi, Neil
Patel, Krupal
Chung, Eun Jae
Howlett, Christopher J.
Plantinga, Paul
Yoo, John
MacNeil, S. Danielle
Fung, Kevin
Mymryk, Joe S.
Barrett, John W.
Palma, David A.
Nichols, Anthony C.
author_sort Ziai, Hedyeh
collection PubMed
description BACKGROUND: Recently, reanalysis of The Cancer Genome Atlas study demonstrated that human papillomavirus (HPV) genotypes in head and neck cancers other than HPV-16 have inferior survival to HPV-16-positive tumors. We aimed to examine the association of HPV subtypes and survival in a large cohort of patient samples from our institution. METHODS: Fresh frozen primary site biopsy samples were collected either in clinic or at the time of surgery. Patient demographic, staging, and survival data were also collected. Tumors were tested for HPV subtypes by quantitative polymerase chain reaction (qPCR). Univariable and multivariable analyses were performed using Cox proportional hazards regression. RESULTS: 280 patient biopsy samples were collected between 2011 and 2017. Mean ± standard deviation (SD) age was 61.9 ± 11.1 years and most patients (78%) were male. The majority of cancers were of the oral cavity (60%) or oropharynx (25%) and 30% had HPV-positive disease. Median follow-up was 3.76 years and 96/280 patients (34%) developed recurrences. Patients with p16-positive versus negative disease had significantly improved 5-year overall survival (OS, 77.6% vs. 53.3%; p=0.009) and progression-free survival (PFS, 67.3% vs. 41.0%, p=0.006). Similarly improved 5-year OS and PFS were observed for patients with HPV-positive versus negative disease (65.0% vs. 55.0%, p=0.084; 53.3% vs. 43.2%, p=0.072, resp.). Patients with HPV-16 compared to other HPV diseases had worse 5-year OS and PFS (62.1% vs. 88.9%, p=0.273; 49.0% vs. 88.9%, p=0.081, resp.). CONCLUSIONS: In contrast to the data derived from The Cancer Genome Atlas, patients with HPV-16 tumors trended towards decreased PFS and OS compared with tumors driven by other HPV genotypes. Further larger multi-institutional studies are necessary to understand the relationship between other HPV genotypes and survival in head and neck squamous cell carcinomas.
format Online
Article
Text
id pubmed-8006754
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-80067542021-04-05 Does HPV Subtype Predict Outcomes in Head and Neck Cancers? Ziai, Hedyeh Warner, Andrew Mundi, Neil Patel, Krupal Chung, Eun Jae Howlett, Christopher J. Plantinga, Paul Yoo, John MacNeil, S. Danielle Fung, Kevin Mymryk, Joe S. Barrett, John W. Palma, David A. Nichols, Anthony C. Int J Otolaryngol Research Article BACKGROUND: Recently, reanalysis of The Cancer Genome Atlas study demonstrated that human papillomavirus (HPV) genotypes in head and neck cancers other than HPV-16 have inferior survival to HPV-16-positive tumors. We aimed to examine the association of HPV subtypes and survival in a large cohort of patient samples from our institution. METHODS: Fresh frozen primary site biopsy samples were collected either in clinic or at the time of surgery. Patient demographic, staging, and survival data were also collected. Tumors were tested for HPV subtypes by quantitative polymerase chain reaction (qPCR). Univariable and multivariable analyses were performed using Cox proportional hazards regression. RESULTS: 280 patient biopsy samples were collected between 2011 and 2017. Mean ± standard deviation (SD) age was 61.9 ± 11.1 years and most patients (78%) were male. The majority of cancers were of the oral cavity (60%) or oropharynx (25%) and 30% had HPV-positive disease. Median follow-up was 3.76 years and 96/280 patients (34%) developed recurrences. Patients with p16-positive versus negative disease had significantly improved 5-year overall survival (OS, 77.6% vs. 53.3%; p=0.009) and progression-free survival (PFS, 67.3% vs. 41.0%, p=0.006). Similarly improved 5-year OS and PFS were observed for patients with HPV-positive versus negative disease (65.0% vs. 55.0%, p=0.084; 53.3% vs. 43.2%, p=0.072, resp.). Patients with HPV-16 compared to other HPV diseases had worse 5-year OS and PFS (62.1% vs. 88.9%, p=0.273; 49.0% vs. 88.9%, p=0.081, resp.). CONCLUSIONS: In contrast to the data derived from The Cancer Genome Atlas, patients with HPV-16 tumors trended towards decreased PFS and OS compared with tumors driven by other HPV genotypes. Further larger multi-institutional studies are necessary to understand the relationship between other HPV genotypes and survival in head and neck squamous cell carcinomas. Hindawi 2021-02-09 /pmc/articles/PMC8006754/ /pubmed/33824664 http://dx.doi.org/10.1155/2021/6672373 Text en Copyright © 2021 Hedyeh Ziai et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ziai, Hedyeh
Warner, Andrew
Mundi, Neil
Patel, Krupal
Chung, Eun Jae
Howlett, Christopher J.
Plantinga, Paul
Yoo, John
MacNeil, S. Danielle
Fung, Kevin
Mymryk, Joe S.
Barrett, John W.
Palma, David A.
Nichols, Anthony C.
Does HPV Subtype Predict Outcomes in Head and Neck Cancers?
title Does HPV Subtype Predict Outcomes in Head and Neck Cancers?
title_full Does HPV Subtype Predict Outcomes in Head and Neck Cancers?
title_fullStr Does HPV Subtype Predict Outcomes in Head and Neck Cancers?
title_full_unstemmed Does HPV Subtype Predict Outcomes in Head and Neck Cancers?
title_short Does HPV Subtype Predict Outcomes in Head and Neck Cancers?
title_sort does hpv subtype predict outcomes in head and neck cancers?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006754/
https://www.ncbi.nlm.nih.gov/pubmed/33824664
http://dx.doi.org/10.1155/2021/6672373
work_keys_str_mv AT ziaihedyeh doeshpvsubtypepredictoutcomesinheadandneckcancers
AT warnerandrew doeshpvsubtypepredictoutcomesinheadandneckcancers
AT mundineil doeshpvsubtypepredictoutcomesinheadandneckcancers
AT patelkrupal doeshpvsubtypepredictoutcomesinheadandneckcancers
AT chungeunjae doeshpvsubtypepredictoutcomesinheadandneckcancers
AT howlettchristopherj doeshpvsubtypepredictoutcomesinheadandneckcancers
AT plantingapaul doeshpvsubtypepredictoutcomesinheadandneckcancers
AT yoojohn doeshpvsubtypepredictoutcomesinheadandneckcancers
AT macneilsdanielle doeshpvsubtypepredictoutcomesinheadandneckcancers
AT fungkevin doeshpvsubtypepredictoutcomesinheadandneckcancers
AT mymrykjoes doeshpvsubtypepredictoutcomesinheadandneckcancers
AT barrettjohnw doeshpvsubtypepredictoutcomesinheadandneckcancers
AT palmadavida doeshpvsubtypepredictoutcomesinheadandneckcancers
AT nicholsanthonyc doeshpvsubtypepredictoutcomesinheadandneckcancers